Crossmark

Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical resection in patients with hepatic Oligometastatic adenocarcinoma of the pancreas (HOLIPANC)

Crossref DOI link: https://doi.org/10.1186/s12885-021-08966-3

Published Online: 2021-11-18

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gebauer, Florian http://orcid.org/0000-0001-5312-4814
Damanakis, Alexander Ioannis

Popp, Felix

Quaas, Alexander

Kütting, Fabian

Lutz, Katrin

Held, Swantje

Deuß, Burkhard

Göser, Tobias

Waldschmidt, Dirk

Bruns, Christiane
Funding

Funding for this research was provided by:

servier

Universitätsklinikum Köln
License Information

Text and Data Mining valid from 2021-11-18

Version of Record valid from 2021-11-18
More Information

Article History

Received: 23 July 2021

Accepted: 4 November 2021

First Online: 18 November 2021

Declarations

:

: The local ethics committee of the University of Cologne (20–1544-AMG) and the local ethic committees of the participating centers throughout Germany approved the study. Patient’s written informed consent prior to any trial-specific procedure must be given before study inclusion.

: not applicable.

: There are no competing interests.

Document is current

Any future updates will be listed below